Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma

Stanford University97 enrolled

Overview

To evaluate the role of purging the hematopoietic cell graft on outcomes for non-Hodgkin's Lymphoma.

To study the use of peripheral blood stem cells which have been treated in an effort to remove tumor cells. The researchers hope to learn whether or not this will be more effective in removing the tumor cells as compared to other methods of purging (the removal of cancer cells).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lymphoma, Non-Hodgkin

Interventions

high dose chemo then auto hematopoietic cell transplantPROCEDURE

Eligibility

Sex: ALLMin age: 4 WeeksMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria:- relapsed NHL Exclusion Criteria:- liver dysfunction

Locations (1)

Stanford University School of Medicine

Stanford, California, United States

Outcomes

Primary Outcomes

PCR positivity in peripheral blood cell collections after cyclophosphamide

Secondary Outcomes

Enrichment of hematopoietic stem cells

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.